Development of SLE among "potential SLE" patients seen in consultation: Long-term follow-up

International Journal of Clinical Practice

Volumn 68, Issue 12, 2014, Pages 1508-1513

  Al Daabil, M ^a   Massarotti, E M ^a   Fine, A ^a   Tsao, H ^a   Ho, P ^a   Schur, P H ^a   Bermas, B L ^a   Costenbader, Karen H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ARTHRITIS; ARTICLE; AUTOIMMUNE THYROIDITIS; CAUCASIAN; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; FIBROMYALGIA; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED CONNECTIVE TISSUE DISEASE; MOUTH ULCER; PATIENT; PATIENT CODING; PATIENT IDENTIFICATION; POTENTIAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT; PREDICTIVE VALUE; PRESCRIPTION; PROTEINURIA; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SJOEGREN SYNDROME; SKIN LUPUS ERYTHEMATOSUS; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TERTIARY CARE CENTER; URINARY CAST; BLOOD; CAUSALITY; COMPLICATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MORTALITY; PATIENT REFERRAL; TIME FACTOR; UTILIZATION;

ADULT; ANTIBODIES, ANTINUCLEAR; CAUSALITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REFERRAL AND CONSULTATION; TIME FACTORS;

EID: 84912016680     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12466     Document Type: Article

References (14)

1. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
3. James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007; 16: 401-9.
4. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33.
5. Panush RS, Greer JM, Morshedian KK,. What is lupus? What is not lupus? Rheum Dis Clin North Am 1993; 19: 223-34.
6. Calvo-Alen J, Alarcon GS, Burgard SL, Burst N, Bartolucci AA, Williams HJ,. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J Rheumatol 1996; 23: 469-75.
7. Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G,. Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol 1998; 17: 195-201.
8. Vila LM, Mayor AM, Valentin AH, Garcia-Soberal M, Vila S,. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus 2000; 9: 110-5.
9. Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007; 56: 2344-51.
10. Mosca M, Tani C, Neri C, Craig F,. Della Rossa A, Baldini C, Talarico R, Carli L, Bombardieri S. [Analysis of the evolution to defined connective tissue diseases of patients with "early unidifferentiated connective tissue diseases (UCTD)"]. Reumatismo 2008; 60: 35-40.
11. Stahl Hallengren C, Nived O, Sturfelt G,. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus 2004; 13: 85-8.
12. Cavazzana I, Franceschini F, Belfiore N, et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheumatol 2001; 19: 403-9.
13. Li QZ, Zhou J, Wandstrat AE, et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol 2007; 147: 60-70.
14. Olsen NJ, Li QZ, Quan J, Wang L, Mutwally A, Karp DR,. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther 2012; 14: R174.